miR-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma
- Shujun Li†1,
- Zhigang Li†1,
- Fengjie Guo1,
- Xuebo Qin1,
- Bin Liu1,
- Zhe Lei2,
- Zuoqing Song1,
- Liya Sun1,
- Hong-Tao Zhang2Email author,
- Jiacong You1Email author and
- Qinghua Zhou1Email author
© Li et al; licensee BioMed Central Ltd. 2011
Received: 11 December 2010
Accepted: 31 March 2011
Published: 31 March 2011
Artemin (ARTN) is a neurotrophic factor belonging to the glial cell-derived neurotrophic factor family of ligands. To develop potential therapy targeting ARTN, we studied the roles of miR-223 in the migration and invasion of human esophageal carcinoma.
ARTN expression levels were detected in esophageal carcinoma cell lines KYSE-150, KYSE-510, EC-9706, TE13, esophageal cancer tissues and paired non-cancerous tissues by Western blot. Artemin siRNA expression vectors were constructed to knockdown of artemin expression mitigated migration and invasiveness in KYSE150 cells. Monolayer wound healing assay and Transwell invasion assay were applied to observe cancer cell migration and invasion. The relative levels of expression were quantified by real-time quantitative PCR.
ARTN expression levels were higher in esophageal carcinoma tissue than in the adjacent tissue and was differentially expressed in various esophageal carcinoma cell lines. ARTN mRNA contains a binding site for miR-223 in the 3'UTR. Co-transfection of a mir-223 expression vector with pMIR-ARTN led to the reduced activity of luciferase in a dual-luciferase reporter gene assay, suggesting that ARTN is a target gene of miR-223. Overexpression of miR-223 decreased expression of ARTN in KYSE150 cells while silencing miR-223 increased expression of ARTN in EC9706 cells. Furthermore, overexpression of miR-223 in KYSE150 cells decreased cell migration and invasion. Silencing of miR-223 in EC9706 cells increased cell migration and invasiveness.
These results reveal that ARTN, a known tumor metastasis-related gene, is a direct target of miR-223 and that miR-223 may have a tumor suppressor function in esophageal carcinoma and could be used in anticancer therapies.
KeywordsmiR-223 ARTN esophageal carcinoma migration and invasion
Artemin (ARTN) is a neurotrophic factor belonging to the glial cell-derived neurotrophic factor (GDNF) family of ligands (GFLs) [1–4], which is important in tumor growth, migration, adhesion and invasion [5, 6]. Increased expression of ARTN has been identified in several human cancers including breast cancer, pancreatic cancer, thyroid carcinoma and endometrial carcinoma [5–10]. Increasing evidence had demonstrated a connection between high expression of ARTN and tumor relapse, metastasis and poor prognosis [7, 8].
MicroRNAs (miRNAs) are a group of small non-coding RNAs (approximately 21-25 nt) that negatively regulate gene expression by imprecisely binding to complementary sequences in the 3' untranslated region (UTR) of their target mRNAs [11, 12]. It has been confirmed that miRNA abnormalities play an important role in gene regulation, apoptosis, the maintenance of cell differentiation and tumorigenesis [13–15]. A recent study has shown that differential expression of miRNAs was correlated with esophageal carcinoma survival [16, 17]. Furthermore, down-regulation of miR-223 was associated with poor prognosis in chronic lymphocytic leukemia [18, 19]. There is emerging evidence that suggests that miR-223 plays an important role in cell proliferation, hematopoietic development and differentiation [20–22]. In this study, we discovered that the expression of ARTN in esophageal carcinoma tissue was higher than that of adjacent tissues, and down-regulation of artemin expression mitigated KYSE150 cell migration and invasiveness. Furthermore, ARTN is a target gene of miR-223. Regulation of miR-223 expression affected the expression of ARTN as well as cell migration and invasion in esophageal carcinoma cells. Finally, we validated that ARTN is a direct target of miR-223 in the context of human esophageal carcinoma.
The human esophageal carcinoma cell lines KYSE-150, KYSE-510, EC-9706 and TE13 were cultured in RPMI-1640 (Invitrogen, Carlsbad, CA) medium supplemented with 10% fetal bovine serum (FBS, GIBCO), 100 IU/ml penicillin and 100 mg/ml streptomycin in humidified 5% CO2 at 37°C. Human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco's minimum essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1 mM sodium pyruvate. For transfection, cells were grown to 80% confluency and transfected with RNAi vector, recombined eukaryotic vector, a chemically synthesized miRNA-223 inhibitor or a negative control using Lipofectamine 2000 (Invitrogen, CA, USA), according to the manufacturer's recommendation.
Collection of tissues
Three samples of esophageal cancer tissues and paired non-cancerous tissues (5 cm away from tumor) were obtained from The Second Hospital of He Bei Medical University. The tissue samples were collected with written consent from the patients. The resected tissue samples were immediately cut into small pieces and snap frozen in liquid nitrogen until use. All tumor tissue and paired non-cancerous tissue samples were pathologically confirmed.
Western blot analysis
Purified esophageal cancer antigen in cold lysate buffer (50 mmol/L Tris-Cl pH 8.0, 150 mmol/L NaCl, 10 mmol/L Triton X-100, 10 mmol/L PMSF) was separated on 10% gradient SDS-polyacrylamide gels in the presence of β-mercaptoethanol. The proteins were transferred onto a NC membrane, blocked with 50 mg/mL fat-free milk in 100 ml PBS for 2 h and incubated with the primary antibody (anti-artemin, R&D Systems) overnight at 4°C. The membrane was washed and then incubated with HRP-conjugated goat anti-rat IgG/IgM (Sigma-Aldrich) at RT for 1 h. The membrane was washed again, and the antigen-antibody reaction was visualized using an ECL detection system. The band intensity was quantified by arithmetic analysis using the software Scion Image beta 4.03. The ratio of artemin/β-actin in each sample was used for statistical analysis.
Construction of artemin siRNA expression vectors
To knock down artemin expression, we used a pSilencer 2.1 vector encoding a small hairpin RNA directed against the target gene in KYSE-150 cells. The target sequence for artemin was 5'- AACAGCACCTGGAGAACCGTG -3' (KYSE-150/RNAi). As a negative control, we used an shRNA vector without the hairpin oligonucleotides (KYSE-150/NC).
Monolayer wound healing assay
Migration ability was determined using a wound-healing assay. Cells were grown in 10% FBS medium on 60 mm plates. After the cells reached sub-confluence, the cells were wounded by scraping the monolayer and grown in medium for 48 h. The width of the wound was measured at different time points. Three to four different locations were visualized and photographed under a phase-contrast inverted microscope (40× objective, Leica, Solms, Germany).
Transwell invasion assay
Cell invasion assays were performed using 24-well transwells (8 mm pore size, Corning Life Sciences) coated with matrigel (1 mg/ml, BD Sciences). Cells (104/well) were seeded in the upper chambers of the wells in 200 μl FBS-free medium, and the lower chambers were filled with 500 μl 10% FBS medium to induce cell migration. Following incubation for 24 h, the cells on the filter surface were fixed with 4% formaldehyde, stained with 0.5% crystal violet, and examined under a microscope. Cells in at least six random microscopic fields (200×) were counted.
Plasmid construction and luciferase reporter assay
Primer sequences of expression vectors construction
Luciferase assays were conducted using 1 × 104 HEK 293 cells plated on a 96-well plate. Co-transfection was performed using 2 ng pMIR-ARTN, pMIR-ARTN-Mut or pMIR-GLO™ empty vector and either 80 ng miRNA expression vector or pcDNA 3.1(+) empty vector. Forty-eight hours after transfection, the cells were harvested and assayed for both firefly and renilla luciferase using the dual-luciferase glow assay (Promega, Madison, WI). All transfection experiments were conducted in triplicate.
Real-time quantitative PCR
Primer sequences of products expression
Cells (1.0 × 104 cells/ml) were cultured in 96-well plates for varying periods of time and exposed to fresh media every other day. During the last 4 h of each day of culture, the cells were treated with methyl thiazolyl tetrazolium (MTT, 50 μg per well, Sigma, USA). The generated formazan was dissolved in DMSO, and the absorbance at 570 nm was measured to measure cell viability.
Data are expressed as mean ± SEM. The difference among groups was determined by ANOVA analysis and comparison between two groups was analyzed by the Student's t-test using GraphPad Prism software version 4.0 (GraphPad Software, Inc., San Diego, CA). A value of P < 0.05 was considered statistically significant.
Expression of ARTN in human esophageal carcinoma tissues and cell lines
Effect of down-regulated artemin expression on the migration of KYSE150 cells
Next, we examined the impact of artemin expression on the migration of KYSE150 cells by a wound healing assay, shown in Figure 2(C). Following incubation of physically-wounded cells for 48 h, KYSE150/RNAi cells had traveled a significantly shorter distance than control cells [Figure 2(D)]. To analyze invasiveness, another important feature of malignant cells, we performed transwell invasion assays using cell culture inserts covered with extracellular matrix components. KYSE150 and KYSE150/NC cells had strong invasive abilities while inhibition of artemin resulted in a massive reduction in invasion (Figure 2E and 2F). The wound healing and invasion assays indicate that down-regulation of artemin expression reduces the migration of KYSE150 cells.
miR-223 interacts with the ARTN 3'UTR and regulates endogenous ARTN protein expression
To identify potential miRNAs that specifically target and regulate ARTN, we used bioinformatic web-based servers including miRBase, TargetScan and Pictar, to scan the 3'UTR of ARTN for miRNAs binding sites. As a result, the three miRNAs with the highest free energy (hsa-mir-105, hsa-mir-223 and hsa-mir-760) were chosen. The seed regions for the three miRNAs for the ARTN 3'UTR are shown in Additional file 1, Figure S1A.
To further study the potential relationship between miR-223 and ARTN, we analyzed miR-223 and ARTN expression level in esophageal cancer tissues. The negative correlation of miR-223 and ARTN expression was found (Figure 3C). We also analyzed miR-223 expression level in four esophageal squamous cell lines (KYSE150, KYSE510, TE13 and EC9706). High expression of miR-223 was detected in KYSE150 and KYST510 cell lines, while low expression of miR-223 was detected in EC9706 and TE13 cell lines (Figure 3D). Interestingly, ARTN expression levels were higher in KYSE150 and KYSE510 than in EC9706 and TE13 cell lines, suggesting that expression of miR-223 was inversely related to ARTN protein level in esophageal carcinoma. KYSE150 and EC9706 were used as models to further investigate the function of miR-223 in esophageal squamous cell carcinoma. We transfected pcDNA3.1 (+)-miR-223 and pcDNA3.1 (+) empty vector into KYSE150 cells and observed a decrease of ARTN protein level in the presence if miR-223 (Figure 3E). Consistent with this result, silencing of miR-223 using an miR-223 inhibitor resulted in an increase of ARTN protein level in EC9706 cells (Figure 3F). These results indicate that ARTN is post-transcriptionally regulated by miR-223.
Effect of mir-223 on the migration of esophageal carcinoma cells
The MTT assay was used to study cell proliferation. KYSE150 cells were transfected with pcDNA3.1 (+) or pcDNA3.1 (+)-miR-223 prior to the proliferation assy. The overexpression of mir-223 did not inhibit proliferation of KYSE150 cells. The morphology of KYSE150 cells transfected with either pcDNA3.1 (+) or pcDNA3.1 (+)-miR-223 did not change compared to the untreated group, and no difference in cell viability between the three groups was observed (Additional file 2, Figure S2A). In EC9706 cells, the morphology and proliferation did not change when the cells were transfected with a mir-223 inhibitor or Scr-miR-223. (Additional file 2, Figure S2B). The MTT assay demonstrates that miR-223 does not significantly influence the proliferation of esophageal carcinoma cells.
To examine invasion, KYSE150 cells were transfected with either pcDNA3.1 (+)-miR-223 or pcDNA3.1 (+) and reseeded on top of the insert. Consistent with the migration results, overexpression of miR-223 significantly inhibited invasion of KYSE150 cells (Figure 4E, F). EC9706 cells, which have a high level of endogenous miR-223, were transfected with an miR-223 inhibitor or a negative control. The EC9706 cells transfected with the miR-223 inhibitor could effectively penetrate the chamber and travel to the other side of the membrane (Figure 4G, H). Matrix metalloproteinases (MMPs) comprise a family of secreted or membrane-associated zinc-dependent extracellular endopeptidases that enhance invasion and metastases. To determine if increased invasion observed was associated with concomitant change of MMP levels, expression of MMP-2 and MMP-9 were performed. MMP-2 and MMP-9 levels were decreased following up-regulation of miR-223, whereas MMP-2 and MMP-9 levels were increased by inhibition of miR-223 (Figure 4I, G). These observations indicate that miR-223 can inhibit invasion in human esophageal carcinoma cell lines.
Tumor metastasis is a complex multistep process including cell adhesion, migration, angiogenesis, immune escape, and homing to target organs. Cell motility, invasion and invasion are essential features of the metastatic process. Identifying the molecules and pathways that control cell motility and invasion is critical to understanding cancer metastasis. Accumulating evidence is suggesting that ARTN is involved in cancer metastasis. ARTN has been shown to promote cell migration and invasion in human endometrial cell line . In addition, depletion of ARTN can inhibit breast cancer metastasis in vivo. Consistent with these results, ARTN overexpression induces cell migration and invasion in pancreatic cancer cells [6, 7]. These observations, taken together, indicate that ARTN plays a positive role in migration and invasion of cancer cells. In the present study, we demonstrate that ARTN expression is significantly higher in esophageal carcinoma than in adjacent noninvasive tissues, and that ARTN promotes migration and invasion of esophageal carcinoma cells.
Recently, emerging evidence has implicated miRNAs in metastasis of human cancer. To verify whether ARTN expression is regulated by miRNAs, miR-105, miR-223 and miR-760 were chosen for further study according to the results of a bioinformatic search. We found that miR-223 interacts with the ARTN 3'UTR and regulates endogenous ARTN protein expression. miR-223 was found to be downregulated in breast and ovarian cancer specimens compared to normal ovarian tissues . Down-regulation of miR-223 has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification . In the present study, overexpression of miR-223 leads to a decrease in ARTN function and represses cellular migration and invasion in KYSE150 cells. On the contrary, silencing of miR-223 increases ARTN expression and promotes cellular migration and invasion in EC9706 cells.
In conclusion, ARTN expression levels were significantly higher in esophageal carcinoma than in adjacent noninvasive tissues, and ARTN promoted migration and invasion of esophageal carcinoma cells. Furthermore, ARTN mRNA was a direct and functional target of miR-223. Finally, we revealed that miR-223 overexpression repressed cell migration and invasion in human esophageal carcinoma cell lines. We provided strong evidence that supports a role for ARTN in tumor cell migration and invasion. Future studies should examine how miR-223 is regulated in human cancer and other human diseases and whether both ARTN and miR-223 are targets for therapy.
This work was partly supported by the grants from the Key Project from National Natural Science Foundation of China(No.30430300), National Natural Science Foundation of China (No.81000950), National 973 Program (No.2010CB529405), Tianjin Scientific Innovation System Program (No.07SYSYSF05000, 07SYSYJC27900), China-Sweden Cooperative Foundation (No.09ZCZDSF04100), and Major Project of Tianjin Sci-Tech Support Program (06YFSZSF05300).
- Baloh RH, Gorodinsky A, Golden JP, Tansey MG, Keck CL, Popescu NC, Johnson EM, Milbrandt J: GFRalpha3 is an orphan member of the GDNF/neurturin/persephin receptor family. Proc Natl Acad Sci USA. 1998, 95: 5801-5806. 10.1073/pnas.95.10.5801.PubMed CentralView ArticlePubMedGoogle Scholar
- Worby CA, Vega QC, Chao HH, Seasholtz AF, Thompson RC, Dixon JE: Identification and characterization of GFRalpha-3, a novel Co-receptor belonging to the glial cell line-derived neurotrophic receptor family. J Biol Chem. 1998, 273: 3502-3508. 10.1074/jbc.273.6.3502.View ArticlePubMedGoogle Scholar
- Parkash V, Leppanen VM, Virtanen H, Jurvansuu JM, Bespalov MM, Sidorova YA, Runeberg-Roos P, Saarma M, Goldman A: The structure of the glial cell line-derived neurotrophic factor-coreceptor complex: insights into RET signaling and heparin binding. J Biol Chem. 2008, 283: 35164-35172. 10.1074/jbc.M802543200.PubMed CentralView ArticlePubMedGoogle Scholar
- Lindahl M, Poteryaev D, Yu L, Arumae U, Timmusk T, Bongarzone I, Aiello A, Pierotti MA, Airaksinen MS, Saarma M: Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells. J Biol Chem. 2001, 276: 9344-9351. 10.1074/jbc.M008279200.View ArticlePubMedGoogle Scholar
- Kang J, Perry JK, Pandey V, Fielder GC, Mei B, Qian PX, Wu ZS, Zhu T, Liu DX, Lobie PE: Artemin is oncogenic for human mammary carcinoma cells. Oncogene. 2009, 28: 2034-2045. 10.1038/onc.2009.66.View ArticlePubMedGoogle Scholar
- Ceyhan GO, Schafer KH, Kerscher AG, Rauch U, Demir IE, Kadihasanoglu M, Bohm C, Muller MW, Buchler MW, Giese NA: Nerve growth factor and artemin are paracrine mediators of pancreatic neuropathy in pancreatic adenocarcinoma. Ann Surg. 251: 923-931. 10.1097/SLA.0b013e3181d974d4.Google Scholar
- Ceyhan GO, Giese NA, Erkan M, Kerscher AG, Wente MN, Giese T, Buchler MW, Friess H: The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg. 2006, 244: 274-281. 10.1097/01.sla.0000217642.68697.55.PubMed CentralView ArticlePubMedGoogle Scholar
- Pandey V, Qian PX, Kang J, Perry JK, Mitchell MD, Yin Z, Wu ZS, Liu DX, Zhu T, Lobie PE: Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells. Endocrinology. 151: 909-920. 10.1210/en.2009-0979.Google Scholar
- Ito Y, Okada Y, Sato M, Sawai H, Funahashi H, Murase T, Hayakawa T, Manabe T: Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers. Surgery. 2005, 138: 788-794. 10.1016/j.surg.2005.07.007.View ArticlePubMedGoogle Scholar
- Marsh DJ, Theodosopoulos G, Martin-Schulte K, Richardson AL, Philips J, Roher HD, Delbridge L, Robinson BG: Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2003, 88: 1866-1872. 10.1210/jc.2002-021155.View ArticlePubMedGoogle Scholar
- Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5.View ArticlePubMedGoogle Scholar
- Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005, 433: 769-773. 10.1038/nature03315.View ArticlePubMedGoogle Scholar
- Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007, 39: 673-677. 10.1038/ng2003.View ArticlePubMedGoogle Scholar
- Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6: 259-269. 10.1038/nrc1840.View ArticlePubMedGoogle Scholar
- Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM: bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 2003, 113: 25-36. 10.1016/S0092-8674(03)00231-9.View ArticlePubMedGoogle Scholar
- Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, Li B, Meng X, Ma X, Luo M: Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 2008, 68: 26-33. 10.1158/0008-5472.CAN-06-4418.View ArticlePubMedGoogle Scholar
- Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D: MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 2009, 15: 6192-6200. 10.1158/1078-0432.CCR-09-1467.PubMed CentralView ArticlePubMedGoogle Scholar
- Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Muller-Tidow C, Bohlander SK, Tenen DG, Behre G: Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood. 115: 1768-1778. 10.1182/blood-2009-08-240101.Google Scholar
- Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D, Lagneaux L: microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009, 113: 5237-5245. 10.1182/blood-2008-11-189407.View ArticlePubMedGoogle Scholar
- Sugatani T, Hruska KA: MicroRNA-223 is a key factor in osteoclast differentiation. J Cell Biochem. 2007, 101: 996-999. 10.1002/jcb.21335.View ArticlePubMedGoogle Scholar
- Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, Wong N: MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 2008, 135: 257-269. 10.1053/j.gastro.2008.04.003.View ArticlePubMedGoogle Scholar
- Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, Brummelkamp TR, Fleming MD, Camargo FD: Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008, 451: 1125-1129. 10.1038/nature06607.View ArticlePubMedGoogle Scholar
- Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008, 7: 35-10.1186/1476-4598-7-35.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.